Who is sponsoring TOCIDYS?

TOCIDYS is sponsored by Hospices Civils de Lyon.

What condition does TOCIDYS study?

TOCIDYS studies Fibrous Dysplasia of Bone.

What drugs are being tested in TOCIDYS?

Interventions: Tocilizumab, Placebo.

What is the status of TOCIDYS?

TOCIDYS is currently COMPLETED.

Last reviewed 2025-09-27 · How we verify

TREATMENT OF FIBROUS DYSPLASIA OF BONE WITH TOCILIZUMAB AMONG PATIENTS WHO DO NOT RESPOND TO BISPHOSPHONATES. THE TOCIDYS TRIAL.

NCT01791842 Phase 2 COMPLETED

Bone pain due to fibrous dysplasia of bone is usually treated with bisphosphonates. A small proportion of patients fail to respond adequately. Mutated bone cells produce large amounts of Interleukin-6 (IL-6), with increased bone resorption as a result. Inhibition of IL-6 may be of interest to reduce bone resorption and therefore bone pain. TOCIDYS is a placebo-controlled randomized cross-over trial to test the hypothesis that tocilizumab can reduce bone resorption in those patients with fibrous dysplasia who have already received bisphosphonates.

Details

Lead sponsor	Hospices Civils de Lyon
Phase	Phase 2
Status	COMPLETED
Enrolment	19
Start date	2013-05-05
Completion	2018-06-19

Conditions

Fibrous Dysplasia of Bone

Interventions

Tocilizumab
Placebo

Primary outcomes

serum CTX (type 1 collagen C-terminal breakdown product) — 6 months

Countries

France